GlassScriptPhysician profile
Sandra Kurtin
NPI 1700985009
$200,874.40
in general payments reported to CMS, 2019-2025
27 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70K · 2022: $44K · 2023: $49K · 2024: $14K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $11K · Honoraria: $11K · Food and Beverage: $2,792 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,405.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,980.25 |
| Travel and Lodging | $11,045.81 |
| Honoraria | $10,504.50 |
| Food and Beverage | $2,791.51 |
| Education | $289.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $23,997.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $21,191.39 | 2021-2024 | Calquence |
| Agios Pharmaceuticals, INC. | $18,279.77 | 2022-2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $17,865.08 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $17,828.44 | 2021-2025 | |
| Abbvie INC. | $17,419.29 | 2021-2023 | |
| Glaxosmithkline, LLC. | $15,452.28 | 2021-2025 | Ojjaara |
| Genzyme Corporation | $11,283.88 | 2021-2022 | |
| Celgene Corporation | $10,292.60 | 2021-2023 | |
| Amgen INC. | $8,746.54 | 2021-2023 | Kyprolis |
| Blueprint Medicines Corporation | $7,072.50 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,691.99 | 2022-2023 | Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $5,410.35 | 2021 | |
| Taiho Oncology, INC. | $3,647.31 | 2021-2022 | |
| Pfizer INC. | $2,880.00 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $2,850.00 | 2021 | |
| Janssen Biotech, INC. | $1,913.59 | 2021-2025 | Imbruvica |
| Genentech USA, INC. | $1,857.87 | 2023-2024 | Venclexta |
| Genentech, INC. | $1,850.00 | 2023 | Lunsumio, Columvi |
| Daiichi Sankyo INC. | $1,827.50 | 2023 | |
| Astrazeneca Uk Limited | $1,160.00 | 2025 | Calquence |
| Adc Therapeutics America, INC. | $900.00 | 2022 | |
| Cti Biopharma Corp. | $700.00 | 2022 | |
| Seagen INC. | $425.00 | 2021 | |
| Tg Therapeutics, INC. | $185.00 | 2021 | |
| Astellas Pharma US INC | $98.00 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $49.02 | 2023 | Tazverik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kurtin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.